MicroRNA-218 inhibits gastrointestinal stromal tumor cell and invasion by targeting KIT

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4209-4217

  Fan, Rong ^a   Zhong, Jie ^a   Zheng, Sichang ^a   Wang, Zhengting ^a   Xu, Ying ^a   Li, Shuyi ^a   Zhou, Jie ^a   Yuan, Fei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; GIST; KIT; miR 218; Proliferation

Indexed keywords

KIT PROTEIN; MICRORNA; MICRORNA 218; PROTEIN; UNCLASSIFIED DRUG; MIRN218 MICRORNA, HUMAN; STEM CELL FACTOR RECEPTOR;

ADHERENT CELL; APOPTOSIS; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; GASTROINTESTINAL STROMAL TUMOR; GENE FUNCTION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; TUMOR CELL; TUMOR INVASION; CELL SURVIVAL; GASTROINTESTINAL TUMOR; GENETICS; PATHOLOGY; PHYSIOLOGY;

APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84902970044     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1551-z     Document Type: Article

References (43)

1. Kanda T. Criminal or bystander: imatinib and second primary malignancy in GIST patients. Chin J Cancer Res. 2013;25(5):490-2.
2. Datar M, Khanna R. Inpatient burden of gastrointestinal stromal tumors in the United States. J Gastrointest Oncol. 2012;3(4):335-41.
3. Li ZY, Tang L, Li SX, Shan F, Bu ZD, Ji JF. Imatinib mesylate in clinically suspected gastric stromal tumors. Chin J Cancer Res. 2013;25(5):600-2.
4. Patel S. Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway. Curr Oncol Rep. 2013;15(4):386-95.
5. Patel S. Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer Chemother Pharmacol. 2013;72(2):277-86.
6. Kinross KM, Sheppard KE, Pearson RB, Phillips WA. Targeting cancer with PI3K pathway inhibitors: who to aim at? Transl Cancer Res. 2012;1(2):119-21.
7. Tan CJ, Yang JL, Crowe P, Goldstein D. Targeted therapy in soft tissue sarcoma - a novel direction in therapeutics. Chin Clin Oncol. 2013;2(3):22.
8. Zhao X, Yue C. Gastrointestinal stromal tumor. J Gastrointest Oncol. 2012;3(3):189-208.
9. Eisenberg BL, Pipas JM. Gastrointestinal stromal tumor - background, pathology, treatment. Hematol Oncol Clin N Am. 2012;26(6):1239-59.
10. Kee D, Zalcberg JR. Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors. Ther Adv Med Oncol. 2012;4(5):255-70.
11. Wang C, Jin MS, Zou YB, Gao JN, Li XB, Peng F, et al. Diagnostic significance of DOG-1 and PKC-theta expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours. Scand J Gastroenterol. 2013;48(9):1055-65.
12. Gao J, Tian Y, Li J, Sun N, Yuan J, Shen L. Secondarymutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors. Med Oncol. 2013;30(2):522.
13. Katz SC, Burga RA, Naheed S, Licata LA, Thorn M, Osgood D, et al. Anti-KIT designer Tcells for the treatment of gastrointestinal stromal tumor. J Transl Med. 2013;11:46.
14. Stankov K, Popovic S, and Mikov M (2014) C-KIT signaling in cancer treatment. Curr Pharm Des (in press)
15. Liang J, Wu YL, Chen BJ, Zhang W, Tanaka Y, Sugiyama H. The Ckit receptor-mediated signal transduction and tumor-related diseases. Int J Biol Sci. 2013;9(5):435-43.
16. Fraser L, Taylor AH, Forrester LM. SCF/KIT inhibition has a cumulative but reversible effect on the self-renewal of embryonic stem cells and on the survival of differentiating cells. Cell Reprogram. 2013;15(4):259-68.
17. Alessandrini L, Parrozzani R, Bertorelle R, Valentini E, Candiotto C, Giacomelli L, et al. C-Kit SCF receptor (CD117) expression and KIT gene mutation in conjunctival pigmented lesions. Acta Ophthalmol. 2013;91(8):e641-5.
18. Kazi JU, Vaapil M, Agarwal S, Bracco E, Pahlman S, Ronnstrand L. The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling. Cell Signal. 2013;25(9):1852-60.
19. D'Allard D, Gay J, Descarpentries C, Frisan E, Adam K, Verdier F, et al. Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket. PLoS One. 2013;8(4):e60961.
20. Jin QH, Shen HX, Wang H, Shou QY, Liu Q. Curcumin improves expression of SCF/c-kit through attenuating oxidative stress and NF-kappaB activation in gastric tissues of diabetic gastroparesis rats. Diabetol Metab Syndr. 2013;5(1):12.
21. Qiu C, Liu X, Bai C, Ma DL. The expression of KIT receptor dimers in gastrointestinal stromal tumors independent of c-kit mutation and SCF expression is associated with high-risk stratification. Oncol Lett. 2012;4(4):805-11.
22. Wang Q, Wei L, Guan X, Wu Y, Zou Q, Ji Z. Briefing in family characteristics of microRNAs and their applications in cancer research. Biochim Biophys Acta. 2014;1844:191-7.
23. Kaplan BB, Kar AN, Gioio AE, Aschrafi A. MicroRNAs in the axon and presynaptic nerve terminal. Front Cell Neurosci. 2013;7:126.
24. Li M, Fu W, Wo L, Shu X, Liu F, Li C. miR-128 and its target genes in tumorigenesis and metastasis. Exp Cell Res. 2013;319(20):3059-64.
25. Leite-Moreira AM, Lourenco AP, Falcao-Pires I, Leite-Moreira AF. Pivotal role of microRNAs in cardiac physiology and heart failure. Drug Discov Today. 2013;18:1243-9.
26. Piva R, Spandidos DA, Gambari R. From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (review). Int J Oncol. 2013;43(4):985-94.
27. Palumbo S, Miracco C, Pirtoli L, Comincini S. Emerging roles of microRNA in modulating cell-death processes inmalignant glioma. J Cell Physiol. 2013;229(3):277-86.
28. Zhang WC, Liu J, Xu X, Wang G. The role of microRNAs in lung cancer progression. Med Oncol. 2013;30(3):675.
29. Yu JJ, Xia SJ. Novel role of microRNAs in prostate cancer. Chin Med J (Engl). 2013;126(15):2960-4.
30. Shi Y, Wang CZ, Hou YY, He DM, Xu C, Liu YL, et al. Screening of differentially expressed microRNAs in borderline and malignant gastrointestinal stromal tumors. Zhonghua Bing Li Xue Za Zhi. 2013;42(1):20-5.
31. Tu Y, Gao X, Li G, Fu H, Cui D, Liu H, et al.MicroRNA-218 inhibits glioma invasion, migration, proliferation and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res. 2013;73(19):6046-55.
32. Jin J, Cai L, Liu ZM, Zhou XS. miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev. 2013;14(6):3681-4.
33. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524-9. (Pubitemid 35403967)
34. Cho WC. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets. 2012;16:747-59.
35. Zhang J, Ma L. MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Rev. 2012;31(3-4): 653-62.
36. Izzotti A, Cartiglia C, Steele VE, De Flora S. MicroRNAs as targets for dietary and pharmacological inhibitors of mutagenesis and carcinogenesis. Mutat Res. 2012;751(2):287-303.
37. Vira D, Basak SK, Veena MS, Wang MB, Batra RK, Srivatsan ES. Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metastasis Rev. 2012;31(3-4):733-51.
38. Link A, Kupcinskas J, Wex T, Malfertheiner P. Macro-role of microRNA in gastric cancer. Dig Dis. 2012;30(3):255-67.
39. Karsy M, Arslan E, Moy F. Current progress on understanding microRNAs in glioblastoma multiforme. Genes Cancer. 2012;3(1):3-15.
40. Shi J, Yang L, Wang T, Zhang J, Guo X, Huo X, et al. miR-218 is downregulated and directly targets SH3GL1 in childhood medulloblastoma. Mol Med Rep. 2013;8(4):1111-7.
41. Guan H, Wei G, Wu J, Fang D, Liao Z, Xiao H, et al. Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer. J Clin Endocrinol Metab. 2013;98(8):E1334-44.
42. Metildi CA, Tang CM, Kaushal S, Leonard SY, Magistri P, Tran Cao HS, et al. In vivo fluorescence imaging of gastrointestinal stromal tumors using fluorophore-conjugated anti-KIT antibody. Ann Surg Oncol. 2013;20:693-700.
43. Halpern J, Kim YJ, Sultana R, Villani G. Effectiveness of radiation therapy in GIST: a case report. J Gastrointest Oncol. 2012;3(2):143-6.